Find a Tender
planned
Official procurement procedure
MHRA specials licenced manufacturing facility
Medical equipments
pharmaceuticals and personal care products
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Northumbria Healthcare NHS Foundation Trust: "MHRA specials licenced manufacturing facility". Published status: planned. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Northumbria Healthcare NHS Foundation Trust | Scope & Categories | Not published | Submission Window | planned No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Northumbria Healthcare NHS Foundation Trust
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Northumbria Healthcare NHS Foundation Trust. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
10Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 3 active published awards; 3 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNorthumbria Healthcare NHS Foundation Trust | Procedure methodNot published | Procurement categoryNot published |
Statusplanned | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published23 Jan 2023, 17:59 GMT | Last source update23 Jan 2023, 17:59 GMT | Recurring procurementNot published |
ClassificationMedical equipments, pharmaceuticals and personal care products | ||
Delivery area | ||
OCIDocds-h6vhtk-0399ed | ||
What is being bought
The North East and North Cumbria (NENC) Provider Collaborative is a formal partnership of all 11 NHS Foundation Trusts (FTs) in the region. Together it covers the entire geographical footprint of the NENC Integrated Care System, from North Yorkshire up to the Scottish borders, and provides the vast majority of all secondary NHS care services with millions of patient interactions every single day.
The NENC Provider Collaborative proposes in this pre market engagement document is to establish a NENC aseptics pharmaceutical production hub at Seaton Delaval, as part of a hub and spoke model, with four initial key priority areas:
1. Injectable chemotherapy medicines supply
2. Addressing nursing time currently spent preparing injectable medicines (primarily Ready to Administer (RtA) injectable antibiotic medicines to clinical areas)
3. Parenteral nutrition production
4. Provision of centralised over labelling of medicines
This will deliver substantial benefits improving clinical safety, delivering a reliable supply of products for patient use, freeing up capacity on hospital sites and directly releasing significant nursing time for patient care.
NENC PC are looking to assess the feasibility of establishing an MHRA specials licenced manufacturing facility capable of meeting GMP, quality and operational requirements.
The proposed output of this facility will be:
• 950,000 Ready to Administer (RtA) products
• 70,000 Systemic anti-cancer therapies and Monoclonal antibodies
• 70,000 Parenteral Nutrition products.
• 400,000 - 600,000 over labelled products.
NHFM is conducting a preliminary market consultation in accordance with the Public Contracts Regulations 2015 reg. 40 with interested organisations to be held on the 10th and 14th February 2023 details of which can be downloaded from the NHFM e-tender Portal https://procontract.due-north.com reference number DN652731
Following the event companies will be required to complete a questionnaire which must be returned via the NHFM e tender portal no later that 12:00 Noon on 24/2/23.
What changed
From the official release history
- Status changed to planned
23 Jan 2023, 17:59 GMT - Official notice release published
23 Jan 2023, 17:59 GMT - Buyer information updated
23 Jan 2023, 17:59 GMT
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedplannedPublished valueNot publishedThe NENC PC are looking to assess the feasibility of establishing an MHRA specials licenced manufacturing facility capable of meeting GMP, quality and operational requirements. The proposed output of this facility will be: • 950,000 Ready to Administer (RtA) products • 70,000 Systemic anti-cancer therapies and Monoclonal antibodies • 70,000 Parenteral Nutrition products. • 400,000 - 600,000 over labelled products.Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
23 Jan 2023, 17:59 GMT
Commercial outcome and competition
AwardsNo award published |
ContractsNo contract published |
Bid statisticsNo aggregate bid statistics published |
Buyer and organisations in this procedure
Northumbria Healthcare NHS Foundation Trust
Contracting authority GB-FTS-54285Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published